59554-11-9

Basic information

• Product Name: (5R,3aR,11bR)-4'α-Acetyloxy-3',3a,4',5',6',11b-hexahydro-3'α,7-dihydroxy-6'β-methylspiro[5H-furo[3,2-b]naphtho[2,3-d]pyran-5,2'-[2H]pyran]-2,6,11(3H)-trione
• Synonyms: (5R,3aR,11bR)-4'α-Acetyloxy-3',3a,4',5',6',11b-hexahydro-3'α,7-dihydroxy-6'β-methylspiro[5H-furo[3,2-b]naphtho[2,3-d]pyran-5,2'-[2H]pyran]-2,6,11(3H)-trione;Griseusin A
• CAS NO: 59554-11-9
• Molecular Formula: C22H20O10
• Molecular Weight: 444.3882
• Mol File: 59554-11-9.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 748.2°Cat760mmHg
• Flash Point: 265.4°C
• Appearance: /
• Density: 1.59g/cm³
• CAS DataBase Reference: (5R,3aR,11bR)-4'α-Acetyloxy-3',3a,4',5',6',11b-hexahydro-3'α,7-dihydroxy-6'β-methylspiro[5H-furo[3,2-b]naphtho[2,3-d]pyran-5,2'-[2H]pyran]-2,6,11(3H)-trione(CAS DataBase Reference)
• NIST Chemistry Reference: (5R,3aR,11bR)-4'α-Acetyloxy-3',3a,4',5',6',11b-hexahydro-3'α,7-dihydroxy-6'β-methylspiro[5H-furo[3,2-b]naphtho[2,3-d]pyran-5,2'-[2H]pyran]-2,6,11(3H)-trione(59554-11-9)
• EPA Substance Registry System: (5R,3aR,11bR)-4'α-Acetyloxy-3',3a,4',5',6',11b-hexahydro-3'α,7-dihydroxy-6'β-methylspiro[5H-furo[3,2-b]naphtho[2,3-d]pyran-5,2'-[2H]pyran]-2,6,11(3H)-trione(59554-11-9)

Safety Data

• Hazardous Substances Data: 59554-11-9(Hazardous Substances Data)

Upstream product

• 75-36-5 acetyl chloride 
• 869293-25-4 (R)-5-((tert-butyldimethylsilyl)oxy)hex-1-en-3-one 
• 83-56-7 1,5-dihydroxynaphthalene 
• 77189-69-6 5-acetoxy-2-bromo-1,4-naphthoquinone 
• 69008-03-3 2-bromo-5-hydroxy-[1,4]naphthoquinone 

Relevant articles and documents

A Divergent Enantioselective Strategy for the Synthesis of Griseusins

The first enantioselective total synthesis of griseusin A, griseusin C, 4′-deacetyl-griseusin A, and two non-native counterparts in 11–14 steps is reported. This strategy highlights a key hydroxy-directed C H olefination of 1-methylene isochroman with an

Griseusin derivatives and their use as antitumor agents

The present invention relates to specific griseusin derivatives, pharmaceutical compositions comprising said griseusin derivatives and the use of these derivatives for the manufacture of a medicament for the treatment of cancers, particularly for the treatment of human solid cancers.